Oxford Biomedica Solutions
Kelly Walsh is a Senior Scientist I at Oxford Biomedica, having progressed through the ranks from Scientist I to Scientist II since joining in March 2022. Prior experience includes roles as Scientist I at Homology Medicines, Inc. and Associate Scientist III as well as Engineer I at Biogen, focusing on protein pharmaceutical development. Earlier career positions include Associate Scientist II at Mersana Therapeutics and Senior Research Associate at Axcella, alongside graduate research at Boston University under the guidance of Sean J, where a focus was on bacterial cytochrome c peroxidases. Educational qualifications include a Master of Arts in Molecular Biology, Cell Biology, and Biochemistry from Boston University, and a Bachelor of Science in Biochemistry from Stonehill College.
This person is not in the org chart
Oxford Biomedica Solutions
Oxford Biomedica Solutions, LLC is the high-performing, full scope Adeno-Associated Virus (AAV) vector Manufacturing and Innovation joint venture of Oxford Biomedica plc (LSE:OXB) (“Oxford Biomedica” or “the Group”), and Homology Medicines, Inc. (Nasdaq: FIXX) (“Homology”). We offer global pharmaceutical and biotechnology clients innovative manufacturing expertise in AAV and lentiviral-based cell and gene therapies. Oxford Biomedica Solutions LLC provides access to Homology’s innovative and proven end-to-end AAV manufacturing capabilities, and customers also benefit from technical synergies brought in by the Group’s know-how in lentiviral vector manufacturing. This collaborative and complementary vector-based approach has the potential to accelerate our collective mission to improve patients’ lives worldwide.